RRM2 and breast cancer: In summary, our findings strongly support the hypothesis that DDX in combination with palbociclib can potentially treat ER+ and ER− breast cancers and perhaps prevent palbociclib resistance by targeting RRM2, NF-κB, cyclin D1 and pRb.